TDSGF OTC

Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenges. The company's central offering is a telomere analysis platform, which provides both diagnostic insights and prognostic assessments. This platform leverages liquid biopsies and related innovations, with a particular emphasis on applications within oncology (cancer) and neurological diseases. A flagship product, Telo-MM, is a solution designed to equip healthcare professionals with crucial, actionable information for managing Multiple Myeloma, a type of blood cancer. Additionally, the company provides TeloView, a proprietary software platform used to precisely measure specific telomere features unique to each patient. Telo Genomics serves a diverse client base, including pathologists, clinicians, academic researchers, and drug developers. They have a collaborative agreement with the Mayo Clinic to conduct validation studies for their Telo-MM tests concerning multiple myeloma. Founded in 2014, the company was initially known as 3D Signatures Inc. before officially changing its name to Telo Genomics Corp. in April 2019. Its headquarters are located in Toronto, Canada.